IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. PHILLER Special

Application No.: 09/801,089

March 8, 2001 Filed:

For: Modulation of Integrin-Mediated Inna Trail

Group Art Unit: 1644

Examiner: Unknown

Commissioner for Patents Washington, D.C. 20231

REVOCATION OF ORIGINAL POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY

Assignee, COR Therapeutics, Inc. hereby revokes all previous Powers of Attorney in the above action and hereby grants its power of attorney to:

POWER OF ATTORNEY: I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

COR Therapeutics, Inc. a corporation located in the United States, certify that they are the assignees of the entire right, title and interest in the patent identified above by virtue of an assignment from the inventor(s) of the parent application serial no. 08/734,607, recorded at reel 8450 frame 0286.

[] Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

COR Therapeutics, Inc.

Date:

Name:

Patrick Broderick

Title:

General Counsel